Double Bond Pharmaceutical AB and N.N. Alexandrov National Cancer Centre of Belarus has entered into agreement about clinical use of Temodex.
DBP announced 5 december 2016 that the company started a collaboration with N. N. Alexandrov National Cancer Centre of Belarus. The main goal was to get access to skills and resources that are relevant to the development of DBP’s products including Temodex that is a drug against brain cancer. The cooperation has been now further developed through a partnership agreement concerning a follow-up of patients with brain tumors treated in Belarus in N. N. Alexandrov National Centre, which will accelerate the process of making Temodex commercially viable worldwide.
Under the agreement, all patients with brain tumors treated with Temodex will be sampled for analysis of MGMT status. The partnership also means that all routine clinical data from these patients will be exclusively provided to DBP. Number of patients with brain tumor treated at the centre yearly is about 500.
"We want to know as much as possible about the efficacy and safety of Temodex in a routine clinical setting, - says Igor Lokot, CEO of DBP. – the fact that Temodex is already approved as a standard treatment of brain tumors in Belarus helps us greatly, and in this way we can capture all the relevant information about the product before we even start clinical trials globally. "
"It is also very valuable that we already now can analyze the impact of MGMT status on Temodex treatment efficacy in a larger population of patients, - said Dr. Iulia Karlsson, Head of Biomarker and Companion Diagnostics Development in DBP. - This cooperation is a great resource when Phase II clinical trials are carried out, because we then have access to a center with a large number of patients and doctors that are acustomed to the product.
More about N.N. Alexandrov National Cancer Centre of Belarus:
N.N. Alexandrov National Cancer Centre is the leading cancer centre in Belarus. It provides the whole scope of services in the field of diagnosis and treatment of malignant tumors.
N.N. Alexandrov National Cancer Centre is also the greatest medical research institution of the Republic of Belarus. It provides free of charge examination and treatment of Belarusian citizens with malignant tumors and renders paid medical services for foreign citizens and Belarusian citizens without malignant diseases.
For more information, read here .
Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here .
Full Company Name
: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name : DBP B
Share ISIN code : SE0007185525
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.
This information is information that Double Bond Pharmaceutical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10th of January 2017 .